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ABSTRACT
Human platelets were identified in tumors by Trousseau in 1865, although their 
roles in tumor microenvironments have only recently attracted the attention of cancer 
researchers. In this study we exploit and enhance platelet interactions in tumor 
microenvironments by introducing tumor-targeting and imaging functions. The first 
step in repurposing human platelets as vehicles for tumor-targeting was to inhibit 
platelet-aggregation by cytoplasmic-loading of kabiramide (KabC), a potent inhibitor 
of actin polymerization and membrane protrusion. KabC-Platelets can accumulate high 
levels of other membrane-permeable cytoxins and probes, including epidoxorubicin, 
carboxyfluorescein di-ester and chlorin-e6. Finally, mild reaction conditions were 
developed to couple tumor-targeting proteins and antibodies to KabC-platelets. 
Fluorescence microscopy studies showed KabC-platelets, surface-coupled with 
transferrin and Cy5, bind specifically to RPMI8226 and K562 cells, both of which 
over-express the transferrin receptor. Repurposed platelets circulate for upto 9-days 
a feature that increases their chance of interacting with target cells. KabC-platelets, 
surface-coupled with transferrin and Cy7, or chlorin-e6, and injected in immuno-
compromised mice were shown to accumulate specifically in sub-cutaneous and intra-
cranial myeloma xenotransplants. The high-contrast, in vivo fluorescence images 
recorded from repurposed platelets within early-stage myeloma is a consequence in 
part of their large size (φ~2µm), which allows them to transport 100 to 1000-times 
more targeting-protein and probe molecules respectively. Human platelets can be 
configured with a plurality of therapeutic and targeting antibodies to help stage tumor 
environments for an immunotherapy, or with combinations of therapeutic antibodies 
and therapeutic agents to target and treat cardiovascular and neurologic diseases.
INTRODUCTION
Platelets are generated from cytomegakaryocytes as 
discoid shaped, closed membrane, anucleate cytoplasmic 
fragments with a diameter of ~2µm. Human platelets 
circulate in the vascular system for about 9-days where 
they have essential roles in hemostasis and inflammation 
[1-4]. A typical adult contains ~4x1012 platelets, and 
each day, ~108 older platelets are removed and ~108 new 
platelets are produced by cytomegakaryocytes [3]. While 
primarily confined to the blood, platelets can gain access 
to the tumor microenvironment via passive diffusion 
across leaky capillaries, or through associations with 
neutrophils and other immune cells [1, 2, 4]. We reasoned 
it should be possible to exploit and to further enhance this 
privileged access to tumor microenvironments by ex vivo 
engineering human platelets with tumor-targeting proteins, 
imaging probes and cytotoxins. Repurposed platelets 
represent a new class of living vehicle for in vivo imaging, 
and targeted-delivery of protein therapeutics or small 
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molecule cytotoxins to tumors. We have developed simple 
protocols to repurpose human platelets for these roles that 
involve: (a), inhibiting platelet aggregation; (b), loading 
the platelet cytosol with detection probes for in vivo 
imaging; (c), loading the platelet cytosol with cytotoxins 
for drug delivery; (d), linking targeting antibodies or 
protein ligands to the platelet surface for tumor targeting. 
Repurposed platelets have several advantages over 
artificial nanoparticles for in vivo targeting and imaging 
of tumor cells. First, platelets are recognized as self by 
the host, and they are widely transfused into patients 
as part of a cancer therapy [5]. Second, platelets have 
privileged access to tumor microenvironments where 
they may interact with tumor cells and immune cells [1, 
4]. Third, platelets are cleared exclusively in the liver or 
spleen after an average circulation time of 9-days [1], 
whereas nanoparticle-derived vehicles [6] are typically 
cleared within 3~5 hours by macrophages and the liver 
[7]. This short circulation time reduces the chance for 
encounters with tumor cells, and especially those deep 
in the tumor. On the other hand, the longer circulation 
of injected platelets increases their chance of interacting 
with target tumor cells. Moreover, the rapid removal of 
nanoparticles loaded with cytotoxins would expose the 
liver to high levels of cytotoxin that could trigger liver 
damage. Interestingly, a recently described approach to 
lengthen the circulation time of injected nanoparticles 
involves cloaking the nanoparticle surface with fragments 
of platelet membranes [8]. Fourth, human platelets 
are much larger than most nanoparticles (φ ∼ 2 µm 
vs < 0.2 µm, respectively), and in principle they can 
accommodate many more surface-coupled targeting 
proteins, and internalized probes (~100-fold and 1000-fold 
respectively).
Platelet-activation is characterized by the formation 
of numerous actin polymerization-driven membrane 
protrusions that promote platelet-aggregation and 
clumping [5, 9]. Platelet-aggregation prevents their 
application as stand-alone vehicles for tumor-targeting. 
We have developed simple approaches to suppress both 
specific and non-specific platelet-aggregation, one of 
which involves loading platelets with kabiramide C 
(KabC), a natural product membrane permeable drug that 
binds tightly to the barbed-end of the actin filament where 
it effectively inhibits actin polymerization [10-12]. KabC-
loaded platelets do not produce membrane protrusions or 
aggregate on exposure to thrombin, or during the physical 
manipulations used during their transformation to tumor-
targeting vehicles. 
KabC-platelets were configured with one or 
more membrane permeable drugs and detection 
probes, including epidoxorubicin, chlorin e6 and 
carboxyfluorescein diester (CFDA). They were 
subsequently chemically-coupled on their surface with 
tumor-targeting proteins, including maleimide conjugates 
of transferrin and antibodies. Near infra-red (NIR) 
fluorophores used for in vitro and in vivo imaging were 
introduced either by chemical-coupling of Cy5-NHS or 
Cy7-NHS to the surface, or else by loading the cytoplasm 
with a membrane permeable NIR-fluorophore. Confocal 
fluorescence microscopy and fluorescence-activated cell 
sorting (FACS) techniques were used to show KabC-
platelets, surface-coupled with human transferrin and Cy5, 
bind specifically to RPMI8226 multiple myeloma cells 
and K562 leukemia cells, both of which over-express the 
transferrin receptor [13]. KabC-platelets, surface-coupled 
with transferrin and Cy7, were shown using in vivo 
fluorescence imaging to accumulate within RPMI8226 
cell-derived myeloma xenotransplants in immuno-
compromised mice [14-17]. Our studies also suggest the 
possibility of engineering human platelets to target other 
diseased states in part by introducing surface-coupled 
antibodies against biomarkers unique to the diseased cell.
RESULTS
Suppressing specific and non-specific aggregation 
of human platelets
An essential step in repurposing human platelets as 
vehicles for tumor-targeting is to overcome their tendency 
to aggregate and clump. Platelet aggregation was inhibited 
by the passive loading of freshly acquired, out-dated 
human platelets with KabC or tetramethylrhodamine-
KabC (TMR-KabC) [10, 11]. These drugs block platelet 
aggregation by inhibiting actin polymerization and 
associated formation of membrane protrusions that are 
characteristic of platelet-activation and aggregation 
[9]. Confocal fluorescence images of human platelets 
incubated with TMR-KabC show the drug accumulates 
in the cytosol where it produces a strong emission that 
allows for high-contrast imaging of individual platelets 
(Figure 1A). The concentration and incubation-time 
dependence of TMR-KabC and KabC-loading of platelets 
was investigated further by recording the intensity of 
TMR-fluorescence in platelets (Supplementary Figure 1). 
The intensity of TMR-fluorescence in platelets increased 
as a function of the incubation time, and it did not saturate 
over the concentration range of TMR-KabC used in this 
study (0~5 µM), which would suggest platelets could 
accumulate an even higher concentration of the probe. 
The final (standard) condition that emerged from these 
analyses was to incubate ~108 platelets with KabC (5µM) 
in mHBSS for 15-minutes at 22oC, followed by low-
speed centrifugation and washing with mHBSS. The 
standard KabC-loading condition resulted in 95.8% of 
platelets having a TMR-fluorescence signal that exceeded 
the highest fluorescence signal recorded for untreated 
platelets (Figure 1B). The finding that platelets sequester 
TMR-KabC (and KabC) in their cytosol was expected, as 
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Figure 1: Characterization and analysis of tumor-targeting platelets. A. Confocal fluorescence image showing the accumulation 
of TMR-KabC in a field of human platelets. Bar = 10 µm. B. FACS analysis of TMR-KabC loading of purified human platelets recorded 
24-hours after incubating with 108 platelets/ml with TMR-KabC at 5 µM. C. Confocal fluorescence image of the intrinsic fluorescence of 
EPI in KabC-platelets. Bar = 10 µm. D. Confocal fluorescence image of KabC-platelets loaded with CFDA. CFDA is de-esterified within 
the platelet to produce a fluorescent di-anionic fluorescein probe that is trapped in the cytosol. Measure bar = 10 µm. E. FACS analysis 
of KabC-platelets without any probe labeling. F. FACS analysis of KabC-platelets loaded with a 30µM solution of chlorin-e6 in KabC-
platelets and recorded 24-hours later. 
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both drugs are cell permeable and are effectively trapped 
in the platelet via their interactions with actin (~400 µM, 
9-12]. Proof that TMR-KabC and KabC were effective 
in suppressing thrombin-mediated platelet aggregation 
was provided by scanning electron microscopy (SEM) 
and transmission electron microscopy (TEM) analyses of 
thrombin-treated platelets loaded with, or without KabC 
(Figure 2A, 2B and 2C, 2D, respectively). Platelets loaded 
with KabC that were exposed to thrombin maintained the 
characteristic smooth and spherical shape of the non-
aggregated platelet (Figure 2A, 2B), whereas platelets 
lacking KabC and treated with thrombin were irregular in 
shape and displayed numerous long membrane protrusions 
that are characteristic of activated and aggregated platelets 
(Figure 2C, 2D). 
Loading platelets with cytotoxins, NIR-
fluorophores and photodynamic therapy probes
Having successfully inhibited platelet-aggregation 
with KabC, we used confocal fluorescence microscopy 
and FACS analyses to optimize the experimental 
conditions used to load KabC-platelets with other 
membrane permeable drugs and detection probes. These 
studies showed platelets accumulated high levels of 
epidoxorubicin (EPI), a potent and intrinsically fluorescent 
cytotoxin (Figure 1C), CFDA, a fluorogenic probe 
suitable for in vitro fluorescence imaging of platelets 
(Figure 1D), and chlorin-e6, a dual-purpose, red-emitting 
fluorophore and photodynamic probe (Figure 1E, 1F 
[18]). The fluorescence signals of platelets loaded with 
chlorin-e6 platelets exceeded the autofluorescence signal 
of unlabeled platelets by a wide margin (Figure 1E, 1F, 
vertical lines indicate the background intensity threshold 
of unlabeled platelets). The strong fluorescence of CFDA 
and chlorin-e6 within platelets allowed us to record high-
contrast images of individual platelets during a single scan 
of the field using a low power of the 488nm or 639 nm 
light source, respectively. FACS analysis also showed that 
KabC-platelets retained an internalized drug or probe for 
at least 24-hours (Figure 1B, 1F). Finally, FACS analysis 
of the intrinsic fluorescence of EPI within KabC-platelets 
before and after treatment with thrombin did not reveal 
any loss of EPI, which suggests the membrane was not 
compromised by thrombin-treatment (99.6% versus 
99.9%, before and after thrombin treatment respectively; 
Figure 2E, 2F). 
Surface-coupling platelets with targeting proteins 
and NIR fluorescent probes
Mild reaction conditions were developed to link 
human transferrin and tumor-targeting antibodies to 
the outer membrane of KabC-platelets. Transferrin was 
chosen to target RPMI8226 multiple myeloma and K562 
leukemia as previous studies have shown these cells over-
express the transferrin receptor [13]. First, a 5mg/ml 
solution of human transferrin (Sigma) was mixed with an 
excess of 2-iminothiolane (Traut’s reagent) in de-aerated 
PBS to generate thiol groups on the protein [19]. The 
thiolated transferrin conjugate was purified using PD-10 
chromatography in PBS, and subsequently mixed with an 
excess of N,N’-(1,4-phenylene)-dimaleimide (PDM) to 
generate pendant maleimide groups (Transferrin-PDM) 
[20]. In some studies (Figure 3D, 3F and Supplementary 
Figure 2), transferrin-PDM was reacted with Cy5-NHS or 
Cy7-NGS in PBS followed by purification using PD-10 
chromatography. Transferrin conjugates bearing Cy5 and 
maleimide groups were concentrated and stored in 100 µL 
aliquots at -80 oC. Proof that Cy5 probes were chemically-
coupled to transferrin-PDM was provided by SDS-PAGE 
analysis of the transferrin conjugate. The transferrin band 
(~80kD) was deliberately over-loaded in order to visualize 
the Cy5-labeled (blue-colored) 80kD protein along with 
its proteolysed fragments (Figure 3A, 3B). Absorption 
spectrometric analysis of the purified Cy5-transferrin 
conjugate revealed an average labeling ration of ~4.5 
Cy5 molecules (Cy5/transferrin; Figure 3C). The blue-
shifted shoulder in the Cy5-absorption spectrum results 
from molecular interactions between Cy5 molecules on 
the transferrin molecule (Figure 3C; [21]).
Next, we developed a simple protocol to couple 
the doubly-labeled transferrin conjugate (Cy5/PDM) 
to the surface of KabC-platelets. KabC-platelets were 
first incubated with 2-iminothiolane (Traut’s reagent) 
for 15-minutes in de-aerated buffer to generate thiol 
groups on their outer membrane. These platelets were 
washed with de-aerated buffer, centrifuged at low speed, 
and re-suspended in a PBS solution containing 0.2mg/
ml solution of doubly-labeled transferrin conjugate for 
15-minutes followed by centrifugation and re-suspension 
in mHBBS. Chemical-coupling of transferrin-PDM/
Cy5 conjugates to KabC-platelets was confirmed using 
confocal fluorescence microscope imaging (Figure 3D) 
and FACS analysis (Figure 3E, 3F and Supplementary 
Figure 2). A representative overlap image (bright-field 
and Cy5-fluorescence; Figure 3D) shows non-aggregated 
and spherical platelets that are uniformly labeled with 
Cy5. FACS analysis of a larger population of the KabC-
platelets surface-coupled with Cy5/PDM-transferrin 
show more than 99.9% have a Cy5-fluorescence signal 
that exceeds the highest background signal of unlabeled 
platelets (Figure 3F and 3E respectively, with the vertical 
lines indicating the background threshold; Supplementary 
Figure 2). A high level of Cy7-transferrin labeling of 
KabC-platelets is also evident from the blue-colored, 
gravity-sedimented suspension of Cy7-coupled KabC-
platelets (Supplementary Figure 2). 
Two other protocols were developed to prepare 
KabC-platelets surface-coupled with transferrin and 
Cy5 or Cy7. In one protocol thiolated platelets were 
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Figure 2: Characterization of KabC-platelets. A. SEM image of a KabC-platelets previously exposed to thrombin (1U/ml). B. 
TEM image of a single KabC-platelet previously exposed to thrombin (1U/ml). C. SEM image of human platelets without KabC previously 
exposed to 1 U/ml thrombin. D. TEM image of a single human platelet without KabC previously exposed to 1 U/ml thrombin. FACS 
analysis of light-scattering for KabC-platelet loaded with EPI E. before, and F. after an exposure to 1U/ml thrombin. 
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first coupled with a transferrin-PDM conjugate, and the 
platelets reacted separately with 0.2 mg/ml of Cy5-NHS 
or Cy7-NHS. The Cy5 or Cy7-coupled KabC-platelets 
prepared using this protocol were used for studies 
described in Figures 4 and 5, and Supplementary Figure 
3. In the second protocol thiolated KabC-platelets were 
reacted with transferrin that had been doubly-labeled with 
Cy5-NHS and maleimidobenzoic acid succinimide acid 
(MBS). This latter protocol was used to prepare KabC-
platelets with a full cargo of cytotoxins, detection probes 
and surface-coupled targeting proteins within 60-minutes 
of receiving out-dated platelets. Repurposed platelets 
were stable in mHBBS for up to 7-days - for example, 
the thrombin treated KabC-platelets shown in Figure 2A 
had been stored for 7-days at 4o in platelet stabilizing 
buffer before being prepared for imaging in the electron 
microscope. 
In vitro imaging of interactions between 
repurposed platelets and human tumor cells
Next we used confocal fluorescence microscopy 
and FACS analysis to quantify interactions between Cy5/
transferrin-coupled KabC-platelets and RPMI8226 cells 
and K562 cells. We confirmed each of these cell lines 
over-express the transferrin receptor [13] by incubating 
cells with a FITC-labeled primary antibody against the 
human transferrin receptor (Figure 4A, 4B) followed 
by FACS analysis - more than 70% of RPMI8226 cells, 
and > 62% of K562 cells exhibited a FITC-fluorescence 
signal that exceeded the maximum background signal of 
unlabeled cells (indicated by the vertical lines in Figure 
4A, 4B). Fluorescence images of KabC-platelets coupled 
with Cy5 alone, or Cy5 and transferrin were recorded 
after an 8-hour incubation with RPMI8226 cells (Figure 
4C, 4D, 4E), or K562 cells (Figure 4F, 4G, 4H). The 
overlap of the Cy5-fluorescence and bright-field images 
Figure 3: Characterization of transferrin conjugates and their coupling to KabC-platelets. SDS-PAGE images of 
transferrin labeled with Cy5 and PDM showing A. the unstained gel with the light blue color originating from absorption of transferrin 
linked Cy5-probes, and B. the same gel stained with Coumassie Blue. Cy5-labeled transferrin shows up as band at ~80kD in both cases. 
C. Absorption spectrum of the transferrin of Cy5/PDM. Analysis of the absorption data at 650nm (Cy5) and 280 nm (transferrin) is used 
to calculate a labeling ratio of 4.5 Cy5 molecules per transferrin molecule. D. Overlay of the phase-contrast and Cy5-fluorescence images 
of KabC-platelets coupled with transferrin conjugated to Cy5/PDM. Bar = 10 µm E. FACS analysis of the background fluorescence of 
KabC-platelets measured in the Cy5-emission channel. F. FACS analysis of the optimized loading condition developed to couple transferrin 
conjugated to Cy5/PDM to thiol-containing KabC-platelets measured in the Cy5-emission channel.
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for control platelets (Cy5-coupled KabC-platelets without 
transferrin) did not reveal any significant binding of 
platelets to RPMI8226 cells or K562 cells (Figure 4C and 
4F respectively). On the other hand, a significant number 
of KabC-platelets surface-coupled with transferrin and 
Cy5 were found on RPMI8226 cells or K562 cells (Figure 
4D, 4E and 4G, 4H respectively). These studies suggest 
that repurposed platelets bind specifically to RPMI8226 
cells, and K562 cells by interactions between transferrin 
molecules on the platelet membrane, and the large number 
of transferrin receptors on the surface of these cells. The 
Cy5-fluoresence on RPMI8226 cells and K562 cells 
remained spotty even after a long period of incubation, 
which might indicate the large diameter of bound platelets 
prevents their internalization by endocytosis [22]. 
In vivo imaging of tumor-targeting platelets
Next we characterized the in vivo distributions of 
KabC-platelets surface-coupled with Cy7 and transferrin, 
or platelets without transferrin in immuno-compromised 
mice. RPMI8226 cells were injected sub-cutaneously 
on the back of NOD/SCID mice [14-16]. Myeloma 
Figure 4: Characterization of interactions between KabC-platelets and tumor cells. A. FACS analysis of RPMI8226 cells 
stained directly with a FITC-conjugated antibody against human transferrin receptor. B. FACS analysis of K562 cells stained directly 
with a FITC-conjugated antibody against human transferrin receptor. C. Confocal Cy5-fluorescence image of surface-attached RPMI 
8226 cells recorded 8-hours after being incubated with Cy5-coupled KabC-platelets. Bar = 10 µm D. Confocal Cy5-fluorescence image 
of surface-attached RPMI 8226 cells recorded 8-hours after being incubated with KabC-platelets coupled with Cy5 and transferrin. Bar = 
10 µm E. Higher-resolution confocal Cy5-fluorescence image of surface-attached RPMI8226 cells recorded 8-hours after being incubated 
with KabC-platelets coupled with Cy5 and transferrin showing individual surface attached platelets and clusters of Cy5-fluorescence (cyan 
arrows). Bar = 5 µm F. Confocal Cy5-fluorescence image of surface-attached K562 cells recorded 8-hours after being incubated with Cy5-
coupled KabC-platelets. Bar = 10 µm G. Confocal Cy5-fluorescence image of surface-attached K562 cells recorded 8-hours after being 
incubated with KabC-platelets coupled with Cy5 and transferrin. Bar = 10 µm H. Higher-resolution confocal Cy5-fluorescence image 
of surface-attached K562 cells recorded 8-hours after being incubated with KabC-platelets coupled with Cy5 and transferrin showing 
individual surface attached platelets and clusters of Cy5-fluorescence (cyan arrows). Bar = 5 µm
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xenotransplants were visible in mice around 2-4 weeks 
after injecting RPMI8226 cells. RPMI8226 cells were 
used for these studies as they over-express the transferrin 
receptor [13]. Moreover, previous studies have employed 
sub-cutaneous myeloma xenotransplants derived from 
injections of RPMI8226 cells to study the effectiveness 
of antibody-based tumor therapies [14-17]. NOD/SCID 
mice were used as hosts for the myeloma xenotransplant 
described in our studies - animals homozygous for the 
SCID mutation have impaired T and B cell lymphocyte 
development, while the NOD background results in 
deficient natural killer (NK) cell function. Myeloma 
xenotransplants grow more efficiently in NOD/SCID mice 
as a result of their immune deficiency, which facilitates 
the growth of sub-cutaneous and intra-cranial injected 
RPMI8226 cells. The average volume of xenotransplants 
that developed after subcutaneous injection of RPMI8226 
cells reached 80~100 mm3 after 7-10 days , and increased 
Figure 5: in vivo NIR-fluorescence imaging of platelets in mice bearing myeloma xenotransplants. A. Time course of 
Cy7-fluorescence images of a mouse bearing a sub-cutaneous RPMI8226 xenograft on its back injected with Cy7 coupled KabC-platelets 
on day-15. The look up tables presented have units of radiant efficiency (photons.sec-1.cm-2.steradian-1) / µW.cm2. B. Time course of the 
distributions of Cy7-fluorescence in a mouse bearing a sub-cutaneous RPMI8226 cell xenotransplant on its back, and injected with Cy7/
transferrin coupled platelets on day-15. C. Bar graph showing the integrated intensities of Cy7-fluorescence in select organs excised from 
mice injected with Cy7-coupled platelets with transferrin (test) or without transferrin (control). 
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to ~2000 mm3 by ~21 days. 
A Caliper NIR-fluorescence imaging system 
was used to image and analyze the distributions of 
repurposed platelets injected into mice. Sub-cutaneous 
xenotransplants were allowed to develop to ~100mm3 in 
test mice. Test platelets (transferrin) and control platelets 
(no transferrin) were injected separately into the tail veins 
of NOD/SCID mice (n = 3 per group), and whole body 
Cy7-fluorescence images recorded over a period of 6-days. 
Control and test platelets were found throughout the body 
of injected mice during the first 24-hours, as evidenced by 
the strong and uniform Cy7-fluorescence in representative 
mice shown in Figure 5A, 5B. The accumulation of test 
platelets in a representative sub-cutaneous xenotransplant 
was evident about 96-hours after platelet-injection, while 
image contrast improved beyond that time owing to the 
clearance of unbound and aged platelets (Figure 5B at 144 
hours). The targeting of repurposed platelets to myeloma 
xenotransplants was further evaluated by recording 
Cy7-fluorescence from the organs excised from mice 
previously injected with test or control platelets (Figure 
5C). The area-normalized Cy7-fluorescence signals 
from excised tumors was 2.54 times higher for Cy7/
transferrin-coupled KabC-platelets compared to Cy7-
coupled KabC-platelets without transferrin (5.25+/-1.11 
vs 2.07+/-1.12 (photons /s/cm2/sr)/(µW/cm2) respectively). 
The discovery of a weak Cy7-fluorescence signal in the 
excised tumors of mice injected with control platelets was 
not unexpected, as previous studies have shown activated-
platelets do localize to tumors [1, 3, 4]. Cy7-fluorescence 
was also evident in the excised livers of mice injected 
with test or control platelets (13.32+/-2.13 and 16.85+/-
1.78 (photons /s/cm2/sr)/(µW/cm2) respectively), and in 
the spleens of mice injected with test and control platelets 
(1.89+/-0.99 and 2.41+/-0.40 (photons/s/cm2/sr)/(µW/
cm2) respectively). Platelet accumulation in these organs 
was also expected as aged-platelets are known to be 
cleared by Kupfer cells. Interestingly, high levels of Cy7-
fluorescence were also found in the kidneys of both groups 
of mice ([2.79+/-1.37 and 4.33+/-1.49 (photons/s/cm2/sr)/
(µW/cm2] respectively), and in their urine. Given that 
most if not all chemical modifications of Cy7, including 
oxidation and fragmentation, result in a loss of far-red 
absorption and fluorescence (λex ~650nm, λex ~670nm), 
the finding of significant Cy7-fluorescence in the urine of 
injected mice would suggest Cy7 is not modified during 
its residence in the mouse. The effectiveness of test 
platelets in targeting myeloma xenotransplants was further 
evaluated by calculating the ratio of Cy7-fluorescence 
among excised organs (myeloma xenotransplant, liver, 
spleen and kidney). The ratios for the tumor/liver, tumor/
spleen and tumor/kidney in the test and control mice were 
Figure 6: In vivo NIR-fluorescence imaging of platelets in control mice, and in mice bearing intra-cranial myeloma 
xenotransplants. Cy7-fluorescence images of mice bearing intra-cranial xenotransplants that formed after injecting RPMI8226 cells. 
The mice (n = 3) were injected with Cy7/transferrin coupled KabC-platelets on day-5 and the Cy7-fluorescence imaged after 24-hours. Cy7-
fluorescence images from two of these mice are shown in A. and B. show structured fluorescence from their crania. C. Cy7-fluorescence 
image of a control mouse without xenograft injected with Cy7/transferrin coupled KabC-platelets. The look up tables presented has units 
of radiant efficiency (photons.sec-1.cm-2.steradian-1) / µW.cm2. The mouse shown in Figure 6A was imaged by MRI on day-8; D. T1 image 
recorded before and, E. after injecting Magnevist in the tail vein. In a second control group, mice were injected with U87 cells transfected 
with RFP to allow for in vivo imaging of neuroglioblastoma xenotransplants. F. RFP fluorescence from a representative mouse in this group 
showing the locus of the neuroglioblastoma xenotransplants. G. corresponding Cy7-image of the same mouse injected with KabC-platelets 
coupled with transferrin and Cy7. Cy7 emission was not detected in the brain of this or other mice in the group. H. FACS analysis of U87 
cells stained directly with a FITC-conjugated antibody against human transferrin receptor showing the majority of U87 cells express low 
levels of transferrin receptor.
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consistently higher for test platelets compared to control 
platelets, and calculated as 0.37 vs 0.13, 2.71 vs 0.88, and 
2.00 vs 0.61 respectively, with all p-values being less than 
0.05. 
Cy7-coupled platelets were cleared from the head 
regions of mice without intra-cranial tumors from 24 to 
48-hours after their injection into mice, while other sites on 
the dorsal side were cleared from 48 to 96-hours (Figure 
5A and 5B). The faster clearance of Cy7-coupled platelets 
from the head region of injected mice was exploited for 
high-contrast, NIR fluorescence imaging of intra-cranial 
xenotransplants that developed after injecting RPMI8226 
cells. Myeloma xenotransplants grow rapidly in the intra-
cranial cavity, a feature that allowed us to begin imaging 
studies only 5-days after the injection of RPMI8226 cells. 
KabC-platelets coupled with Cy7 and transferrin (test 
platelets) were injected into the tail veins of control mice 
ie those not injected with RPMI8226 cells (n = 3), and 
in test mice that had received intra-cranial injections of 
RPMI8226 cells (n = 3). Images of Cy7-fluorescence 
from the head region of test mice recorded 24-hours after 
injecting test platelets showed a structured fluorescence 
within the cranium (Figure 6A, 6B and Supplementary 
Figure 3C). The presence of Cy7-fluorescence on the 
lower dorsal sides 24-hours after injecting platelets in 
test mice (Figure 6A, 6B and Supplementary Figure 3C) 
did not interfere with our ability to use Cy7-fluorescence 
signals to identify the presence and location of intra-
cranial myeloma transplants. This finding was supported 
by studies on control mice, which showed an absence of 
Cy7-fluorescence 24-hours after injecting test platelets 
(Figure 6C; Supplementary Figure 3A, 3B). Images 
from these control studies also support the view that test 
platelets do not engage in non-specific interactions with 
cells or structures in the head region of mice without 
myeloma xenotransplants. The findings from the in vivo 
Cy7-fluorescence imaging study was confirmed by MR-
imaging of the cranium for the mouse shown in Figure 6A. 
The MRI study was conducted approximately 48-hours 
after injecting repurposed platelets. T1-images of the head 
region of the mouse were recorded immediately before 
and immediately after injecting 100 µL of the contrast-
enhancing MRI probe (Magnevist, 0.1M). A qualitative 
comparison of the two images (Figure 6D and 6E, 
respectively) shows the Magnevist-labeled region in the 
cranium is similar to that identified 24-hours earlier from 
the Cy7-fluorescence (Figure 6A). 
Taken together, in vivo imaging studies show 
injected KabC-platelets coupled with transferrin and Cy7 
(test platelets) accumulate within RPMI8226 cell-derived 
myeloma xenotransplants. in vivo Cy7-fluorescence 
imaging showed accumulations of test platelets within 
early-stage intra-cranial myeloma transplants with 
diameters on the order of ~1 mm. The bright Cy7-
fluorescence recorded from these tumors arises in part 
from the efficient labeling of Cy7 molecules on the surface 
of intact repurposed platelets (diameter ~2µm). Owing to 
differences in their size, repurposed platelets (φ ~2000nm) 
can be surface-coupled with ~100-fold more of a targeting 
protein or Cy7 compared to a nanoparticle (φ ~200nm), 
and ~1000-fold more of an internalized probe or cytotoxin. 
We showed in figure 6C that control mice ie those 
without intra-cranial xenotransplants did not accumulate 
transferrin-coupled KabC platelets in the cranium, while 
control studies detailed in the following section also 
show platelets lacking transferrin do not accumulate to 
significant levels in the crania of mice bearing myeloma 
transplants (Figure 7A). A further control study was 
conducted to show the labeling of intra-cranial myeloma 
xenotransplants with KabC-platelets was dependent 
on interactions between transferrin molecules on the 
surface of the platelet and transferrin receptors on the 
surface of the tumor cell. A control group of mice (n = 
3) were injected intra-cranially with RFP-transfected 
U87 cells that over time developed xenografts [23]. 
These mice were injected in their tail vein with KabC-
platelets coupled with Cy7 and transferrin (test platelets). 
Neuroglioblastoma xenografts were clearly resolved from 
images of RFP-fluorescence that were recorded 120-hours 
after injecting the test platelets (Figure 6F). However, 
Cy7-fluorescence was not detected in the region around 
the RFP-labeled neuroglioblastoma xenotransplant 
(Figure 6G; Supplementary Figure 3D, 3E). Transferrin 
receptor expression levels on U87 cells were analyzed by 
FACS after incubating U87 cells for 30 minutes with a 
FITC-labeled anti-human transferrin receptor antibody. 
Approximately one quarter of the U87 cells showed a 
FITC signal beyond that of the autofluorescence signal the 
(Figure 6H). This study suggests that transferrin-coupled 
KabC-platelets bind to tumor cells that over-express 
the transferrin receptor where they are retained through 
multiple interactions. On the other hand, tumor cells that 
express low levels of the transferrin receptor, and other 
structures within the intra-cranial cavity do not show any 
significant binding to test platelets. With the exception 
of the liver and spleen, which are responsible for platelet 
clearance, we have not observed accumulations of test or 
control platelets in other tissues whose component cells 
express much lower levels of the transferrin receptor 
compared to RPMI8226 cells and K562 cells [13]. Another 
possibility to account for the increased specificity of test 
platelets for RPMI8226 cells in myeloma transplants 
would be if the human transferrin on the platelet had 
a higher affinity for the human transferrin receptor 
molecules on RPMI8226 cells compared to that for the 
murine transferrin receptor.
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Figure 7: Immuno-histochemical imaging and analysis of RPMI8226 cell-derived xenotransplants. Tumor slices excised 
from mice injected with KabC-platelets coupled with transferrin and chlorin e6. Measurement bars in all images is 50 µm: A. in vivo red-
fluorescence image of a representative mouse bearing an intra-cranial xenotransplants that developed after injecting RPMI8226 cells and 
then injected with KabC-platelets loaded with chlorin e6. B. in vivo red-fluorescence image of a representative mouse bearing an intra-
cranial xenotransplants that developed after injecting RPMI8226 cells and then injected with KabC-platelets coupled with transferrin and 
loaded with chlorin e6. C. Representative confocal fluorescence image of a FITC-labeled antibody directed against human transferrin 
receptor showing the distribution of RPMI8226 cells in the tumor slice. D. Bright-field image of the same tumor slice. E. Chlorin e6 
fluorescence in the xenotransplant slice showing the distribution of repurposed platelets in blood vessels and tumor tissue. F. Overlay of the 
FITC, bright-field and red-fluorescence images showing infiltration of platelets within the xenotransplant.
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Immuno-histochemical analysis of repurposed 
platelets in myeloma xenografts
Tissue slices prepared from intra-cranial 
xenotransplants were analyzed by immuno-
histocytochemistry. The purpose of these studies was 
to further investigate the in vivo Cy7-imaging studies 
that showed KabC-platelets coupled with transferrin 
(test platelets) gain access to tumor microenvironments 
where they accumulate as a result of interactions between 
transferrin molecules on the platelets surface and receptor 
molecules on RPMI8226 cells. In this study, KabC-
platelets were loaded with chlorin e6, a membrane 
permeable Cy5-like fluorescence probe that can also 
serve as a photodynamic therapy probe. Chlorin-e6 
accumulates to a high level in the cytoplasm of KabC-
platelets (Figure 1F). Chlorin e6-loaded KabC-platelets 
were divided into two fractions - one fraction was 
surface-coupled with transferrin (test) while the other 
(control) lacked transferrin. Control and test platelets 
were injected separately into the tail veins of mice (n = 3) 
that 5-days earlier had been injected intra-cranially with 
RPMI8226 cells. Chlorin-e6 fluorescence was recorded 
in live tumor-bearing mice using the Cy5 excitation and 
emission channel of the Caliper instrument. The chlorin 
e6 fluorescence was weak in the crania of tumor-bearing 
mice injected with control platelets (ie those lacking 
transferrin; Figure 7A; Supplementary Figure 3F, 3G). 
On the other hand, tumor-bearing mice injected with test 
KabC-platelets emitted fluorescence from their crania 
(Figure 7B, Supplementary Figure 3H, 3I). Tissue slices 
isolated from excised brains of mice injected with test 
platelets loaded with chlorin e6 were fixed using 4% 
paraformaldehyde and frozen-sliced. The fixed tissue 
section was further labeled with a FITC-labeled antibody 
directed against the transferrin receptor. After extensive 
washing, regions from a representative slice of the 
multiple myeloma isolated from the mouse shown in 
Figure 7B were observed visually, and representative 
images of the FITC channel (green; transferrin receptor; 
Figure 7C) and chlorin e6 channel (pink; platelets; Figure 
7E), and bright-field (Figure 7D) were recorded on the 
Zeiss 700 confocal microscope. The three images (FITC 
and chlorin e6 fluorescence, and bright-field) of the 
tumor slice were merged using embedded software in the 
Zeiss instrument (Figure 7F). FITC-fluorescence, which 
serves as a measure of RPMI8826 cells, was distributed 
throughout the tumor tissue (Figure 7C). Chlorin-e6 
fluorescence (pink) was strongest in the blood vessels 
(Figure 7E), although significant fluorescence was also 
evident in the tumor tissue (Figure 7F). The merged image 
of the tumor slice reveals shows considerable overlap in 
the distributions of the transferrin receptor (FITC) and 
test platelets (chlorin e6). On the basis of analyses of 
results from the immunofluorescence-histocytochemical 
analysis and Cy7-fluorescence images of organs excised 
from tumor-bearing mice (Figure 5C), we conclude that 
KabC-platelets surface-coupled with transferrin are 
present within tumor microenvironments where they are 
retained by specific interactions between transferrin on the 
platelet surface and high levels of transferrin receptors on 
RPMI8826 cells. 
DISCUSSION
We have shown that human platelets can be 
repurposed as vehicles for efficient in vitro and in vivo 
targeting and imaging of myeloma xenotransplants by 
coupling targeting proteins and detection probes to their 
surface. The effectiveness of repurposed platelets as 
vehicles for tumor-targeting and imaging is a consequence 
of several unique features that include: (a), privileged 
and deep access to tumor microenvironments; (b), a long 
period of circulation of up to 9-days, which increases 
their chance of encountering a tumor cell compared to 
most nanoparticle vehicles that have circulation times 
on the order of 3~9 hours [7]; (c), greater volume and 
surface area that allows platelets to transport a larger 
cargo of cytotoxins, detection probes and surface-borne 
targeting proteins compared to a nanoparticle [6]; (d), 
repurposed platelets are cleared naturally by Kupfer 
cells in the liver and spleen, which reduce non-specific 
accumulation of labeled platelets at off-target sites. The 
short circulation time of nanoparticles of 3~5 hours [6] 
may help to increase signal contrast of a targeted tissue 
within a few hours of their injection into an animal. This 
advantage however, must be weighed against two very 
negative and application-limiting effects of using vehicles 
with short circulation times. First, the short period of 
circulation reduces the number of molecular encounters 
between the injected nanoparticles and their target cells 
ie most nanoparticles will be cleared by macrophages 
via endocytosis or via the liver before they encounter 
the target. Consequently, effective labeling of a tumor 
requires one to inject large numbers of nanoparticles, 
which also increases the risk of off-targeting. Second, 
in the case of nanoparticles loaded with cytotoxins the 
sudden appearance of high levels of the cytotoxin in the 
liver may overwhelm the detoxification capacity of the 
liver and result in liver damage. The longer circulation of 
platelets (9-days) on the other hand, would increase their 
interactions with targeted cells, while their gradual and 
exclusive clearance by the liver and spleen should help 
to reduce cytoxin-mediated damage to these organs. The 
application of longer-circulating, repurposed platelets as 
tumor-targeting vehicles would also help to reduce the 
number of repeat injections in a cancer treatment. 
Inhibiting platelet-aggregation is an essential step in 
repurposing human platelets as living vehicles for tumor 
targeting and imaging. Platelet-aggregation is blocked 
by passive loading of KabC, or cytochalasin D [24] in 
the cytoplasm where they inhibit actin polymerization 
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and membrane protrusions associated with platelet-
aggregation. We have also used salicylic acid to inhibit 
platelet-activation and aggregation [25]. Platelets 
rendered aggregation-incompetent by treatment with 
KabC can be loaded passively with a variety of membrane 
permeable drugs and detection probes, including chlorin 
e6, CFDA and EPI. The accumulation and retention of 
these molecules in the cytosol was shown by confocal 
fluorescence imaging and FACS. Interestingly, chlorin e6 
may be used as a Cy5-like detection probe as was shown 
in this study, and as photodynamic therapy probe [18]. The 
reactions used to repurpose human platelets for targeted 
imaging of myeloma were optimized using FACS and 
fluorescence microscopy - repurposed platelets configured 
with KabC, EPI, transferrin and Cy7 were prepared within 
an hour of receiving outdated human platelets. Tumors that 
developed after injecting RPMI8226 cells accumulated 
injected KabC-platelets that had been surface-coupled with 
Cy7 and transferrin. These platelets resulted in a strong 
Cy7-fluorescence that was used for in vivo imaging of 
intra-cranial tumors of ~1 mm in diameter. The protocols 
we have developed to repurpose human platelets as 
vehicles for in vivo targeting of myeloma xenotransplants 
can be modified to accommodate a large range of targeting 
ligands and antibodies, and therapeutic agents and 
detection probes. For example, we have recently shown 
that KabC-platelets can be configured with a plurality of 
detection probes, including NIR-fluorophores, Magnevist 
and iron oxide nanoparticles for MR-imaging, and 
therapeutic proteins. Since platelets are found naturally at 
sites of inflammation and tissue damage, their repurposing 
with additional targeting, and therapeutic proteins could 
be used to augment innate immune responses to a disease 
condition, including those associated with cardiovascular 
disease and neurodegenerative disorders. 
Looking forward, recent studies from our group 
indicate additional applications for repurposed platelets 
in translational and precision medicine. These findings 
include demonstrations that platelets coupled with an 
antibody against the protein death ligand-1 bind selectively 
to tumor cells that express PDL-1 [26]. Platelets have also 
been configured with a plurality of antibodies that allow 
for tumor-targeting and T-cell activation.
MATERIALS AND METHODS
RPMI8226 multiple myeloma and K562 leukemia 
cells were obtained from the cell bank of the Chinese 
Academy of Sciences. Human platelets were obtained 
from the Chinese Red Cross within 5 days of drawing 
blood. Platelets were stored in citrate saline (0.006M tri-
sodium citrate/ 0.154M NaCl, pH 6.8) with 5% bovine 
serum albumin at a density of 3-5x108 platelets/ml. After 
centrifugation, platelet pellets were re-suspended in a 
modified Hanks’ buffered salt solution (mHBSS; 0.17M 
NaCl/ 6.7mM KCl/ 1.0mM MgSO4/ 0.5mM K2HPO4/ 
2.8mM Na2HPO4 / 13.8mM dextrose, pH to 7.2 with 
1.4% NaHCO3) for in vitro studies, or in normal saline 
for in vivo studies. KabC and TMR-KabC were prepared 
according to our earlier publications [10-12]. Human 
transferrin, EPI, carboxyfluorescein diacetate (CFDA), 
chlorin E6 (CE6), Phenyl-dimaleimide, maleimide-
benzoic acid succinimide ester and iminothiolane were 
purchased from Sigma. Cy5-NHS and Cy7-NHS were 
both purchased from GE Healthcare. 
Transferrin conjugates
PDM-transferrin was prepared by reacting 
25 μM PBS solution of transferrin with 250 μM of 
2-iminothiolane to generate thiol groups on the protein 
surface. After passage over a PD-10 column in PBS the 
protein fraction was treated with PDM to 250 μM and 
after a 2-hour incubation at 20oC the sample was applied 
to a second PD-10 column to remove excess crosslinker. 
The thiol-reactive conjugate was stored in 100 μL aliquots 
at -20oC. A transferrin conjugate harboring both Cy5 
and maleimide-benzoic acid succinimide ester (MBS) 
was prepared by incubating transferrin (5mg/ml) in 
PBS with Cy5-NHS (0.2mg/ml) and MBS (0.1 mg/
ml) delivered from DMF stock solutions. After a 2-hour 
incubation unbound reactants were removed by PD-10 
chromatography and the protein conjugate characterized 
by absorption spectroscopy and SDS-PAGE and stored 
at -20oC in 100μL aliquots. The MBS/Cy7-conjugate 
of transferrin was prepared using the same protocol. 
Protocols used to couple transferrin conjugates to thiolated 
platelets are described in the Results section.
Confocal fluorescence microscopy
Fluorescence images of probes loaded into the 
cytoplasm or on the surface of platelets, and in mixtures 
of platelets with surface-attached RPMI 8226 or K562 
cells, within immuno-histocytochemical stained frozen 
myeloma xenograft tissue sections were carried out using 
a Zeiss 700 instrument with embedded software that 
allows for excitation of fluorescent probes (CFDA, FITC, 
EPI, TMR, or Cy5) at 488nm, 555nm and 639nm, and 
collection of the fluorescence emission from each probe 
was using a computer-selected filter. 
FACS
A Becton and Dickenson FACS Calibur flow 
cytometer was used to sort and quantify labeled 
populations of free platelets and RPMI8226 or K562 cells. 
These studies recorded 10,000 events for each sample 
using the fluorescence of CFDA, FITC, EPI, TMR, Cy5 
or CE6 that were detected using FL1, FL2, FL3 or FL4 
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channel respectively. The FACS data was analyzed with 
FlowJo V3.2 (Tree Star, Inc.) and represented as the 
percentage of labeled population. 
Electron microscopy
Platelets were prepared for SEM and TEM-imaging 
using an established protocol [27] in a Hitachi 450 SEM 
and a FEI Tecnai G2 Spirit Bio TWIN TEM. Suspensions 
of platelets were fixed chemically by adding an equal 
volume of 0.1% glutaraldehyde for 15-minutes followed 
by centrifugation and re-suspension of the pellets in 3% 
glutaraldehyde. The platelet samples were allowed to 
settle and adhere to glass fragments that were pre-coated 
with poly-lysine. The glass fragments were rinsed with 
distilled water and dried at the critical-point. 
Mice
Analgesic and tranquilizing drugs were used to 
minimize discomfort and pain to animals during injections 
of RPMI8226 cells. NOD/SCID mice are euthanatized 
by cervical dislocation after anesthetization with a 0.016 
mL/g (body weight) solution of 2.5% Avertin that was 
injected intra-peritoneal. Alternatively, death was brought 
about by CO2 anesthesia followed by decapitation. 
Experiments on living mice were carried out according to 
established protocols developed at SouthEast University, 
and were consistent with an animal protocol used by GM 
at UC-Berkeley.
NIR-fluorescence imaging
RPMI8226 cells (1×107 cells in 100μl of buffer) 
were injected under the skin on the backs of NOD/SCID 
mice. In other studies RPMI8226 cells (1×106 cells in 
10μl) were injected through an opening in the skull of 
NOD/SCID mice [14-17]. A minimum number of mice 
were used for these proof of practice studies, and typically 
3 in each data group. NIR fluorescence imaging of live 
mice and their excised organs was carried out using a 
Caliper IVIS Spectrum Imaging System. The instrument 
was used to record the NIR emission spectra of Cy5 and 
Cy7 loaded in platelets within live mice, or from their 
excised organs. The NIR fluorescence images shown in 
this study were processed using software resident in the 
IVIS machine. Prior to in vivo imaging, fur in the vicinity 
of the myeloma xenotransplant was removed from the 
mice by shaving or defoliation.
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